Actively Recruiting
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
Led by University Hospital, Montpellier · Updated on 2025-09-30
85
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.
CONDITIONS
Official Title
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For patients: Provided written informed consent for inclusion in the CART-BANK protocol and oral consent for the CARTROG protocol
- For patients: Aged 18 years or older at inclusion
- For patients: Diagnosed with diffuse large B-cell lymphoma
- For patients: Planned treatment with anti-CD19 CAR-T cells
- For patients: Affiliated with or covered by a social security scheme
- For healthy volunteers: Provided oral informed consent for the CARTROG protocol
- For healthy volunteers: Aged between 18 and 70 years at inclusion
- For healthy volunteers: No history of solid cancer or hematological malignancy
- For healthy volunteers: No known chronic diseases and not taking daily medications
- For healthy volunteers: No surgery within the last 6 months
You will not qualify if you...
- Patients not meeting all inclusion criteria
- Pregnant or breastfeeding patients
- Patients unable to follow study procedures or visit schedule due to psychological, family, social, or geographical reasons
- Patients unable to provide free and informed consent, including those under guardianship, curatorship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Clinical hematology department, University Hospital
Montpellier, France
Actively Recruiting
2
Clinical Investigation Center, University Hospital
Montpellier, France
Actively Recruiting
Research Team
V
Valérie ROUILLE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here